January 10, 2021
Authors Zhigang Wang (1), Bram Verstockt (2,3), João Sabino (2,3), Séverine Vermeire (2,3), Marc Ferrante (2,3), Paul Declerck (1), Erwin Dreesen (1,4)
Affiliations 1. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium 2. Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium 3. Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium 4. Department of Pharmacy, Uppsala University, Uppsala, Sweden
Presentation type Oral
Presenters Zhigang Wang
Background: Ustekinumab is approved for the treatment of patients with moderate-to-severe Crohn’s disease (CD) and ulcerative colitis. In the UNITI endoscopy sub-study, only 17.4% of patients on ustekinumab achieved endoscopic response and 10.9% of patients achieved endoscopic remission at week 44 (w44).1 Aims: We aimed to investigate if improved endoscopic outcomes could be achieved through dose optimization […]